Literature DB >> 11669460

Anxiolytic effect of Kami-Shoyo-San (TJ-24) in mice: possible mediation of neurosteroid synthesis.

M Mizowaki1, K Toriizuka, T Hanawa.   

Abstract

We assessed the anxiolytic effect of Kami-Shoyo-San (Jia-wei-xiao-yao-san; TJ-24), one of a traditional Chinese herbal medicine used for the treatment of menopausal anxiety, by the social interaction (SI) test in male mice. Acute administration of TJ-24 (25-100 mg/kg, p.o.), as well as the gamma-amino-butyric acidA/benzodiazepine (GABA(A)/BZP) receptor agonist diazepam (1-3 mg/kg, i.p.), dose dependently increased the SI time, respectively. The GABA(A) receptor antagonist picrotoxin blocked the effects of TJ-24 and diazepam. TJ-24-induced SI behavior was significantly blocked by the GABA(A)/BZP receptor inverse agonist Ro 15-4513 and the GABA(A)/BZP receptor antagonist flumazenil. In addition, 5alpha-reductase inhibitor finasteride potently blocked the effect of TJ-24 without attenuating the basal level by itself. These findings suggest that TJ-24 shows the anxiolytic effect through the neurosteroid synthesis followed by GABA(A)/BDZ receptor stimulations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11669460     DOI: 10.1016/s0024-3205(01)01290-5

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  Soyo-san reduces depressive-like behavior and proinflammatory cytokines in ovariectomized female rats.

Authors:  Hyun-Jung Park; Hyun-Soo Shim; Sun Yong Chung; Tae Hee Lee; Insop Shim
Journal:  BMC Complement Altern Med       Date:  2014-01-21       Impact factor: 3.659

2.  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Effects of Kamishoyosan, a Traditional Japanese Medicine, on Menopausal Symptoms: The KOSMOS Study.

Authors:  Kiyoshi Takamatsu; Mariko Ogawa; Satoshi Obayashi; Takashi Takeda; Masakazu Terauchi; Tsuyoshi Higuchi; Kiyoko Kato; Toshiro Kubota
Journal:  Evid Based Complement Alternat Med       Date:  2021-02-26       Impact factor: 2.629

3.  Core prescription pattern of Chinese herbal medicine for depressive disorders in Taiwan: a nationwide population-based study.

Authors:  Diem Ngoc Hong Tran; I-Hsuan Hwang; Fun-Jou Chen; Yuan-Pu Tseng; Ching-Mao Chang; Shih-Jen Tsai; Jen-Lin Yang; Ta-Peng Wu; Chung-Hua Hsu; Fang-Pey Chen; Yen-Ying Kung
Journal:  Integr Med Res       Date:  2020-12-04

4.  Room-temperature super-extraction system (RTSES) optimizes the anxiolytic- and antidepressant-like behavioural effects of traditional Xiao-Yao-San in mice.

Authors:  Shih-Hsi Yin; Ching-Cheng Wang; Tain-Junn Cheng; Chia-Yu Chang; Kao-Chang Lin; Wei-Chih Kan; Hsien-Yi Wang; Wenny Mei-Wen Kao; Yen-Liang Kuo; Jian-Chyi Chen; Shun-Lai Li; Chia-Hui Cheng; Jiunn-Jye Chuu
Journal:  Chin Med       Date:  2012-11-07       Impact factor: 5.455

5.  Prescriptions of Chinese Herbal Medicines for Insomnia in Taiwan during 2002.

Authors:  Fang-Pey Chen; Maw-Shiou Jong; Yu-Chun Chen; Yen-Ying Kung; Tzeng-Ji Chen; Fun-Jou Chen; Shinn-Jang Hwang
Journal:  Evid Based Complement Alternat Med       Date:  2010-10-20       Impact factor: 2.629

6.  Effects of Kamishoyosan, a Traditional Japanese Medicine, on Menopausal Symptoms: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial.

Authors:  Kiyoshi Takamatsu; Mariko Ogawa; Tsuyoshi Higuchi; Takashi Takeda; Kunihiko Hayashi; Hideki Mizunuma
Journal:  Evid Based Complement Alternat Med       Date:  2020-07-11       Impact factor: 2.629

7.  Kami-shoyo-san improves ASD-like behaviors caused by decreasing allopregnanolone biosynthesis in an SKF mouse model of autism.

Authors:  Qing-Yun Guo; Ken Ebihara; Takafumi Shimodaira; Hironori Fujiwara; Kazufumi Toume; Dya Fita Dibwe; Suresh Awale; Ryota Araki; Takeshi Yabe; Kinzo Matsumoto
Journal:  PLoS One       Date:  2019-01-31       Impact factor: 3.240

8.  Antidepressive Effects of Kamishoyosan through 5-HT1AReceptor and PKA-CREB-BDNF Signaling in the Hippocampus in Postmenopausal Depression-Model Mice.

Authors:  Shoko Shimizu; Yugo Ishino; Takashi Takeda; Masaya Tohyama; Shingo Miyata
Journal:  Evid Based Complement Alternat Med       Date:  2019-11-03       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.